Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2022 | 1 |
2023 | 2 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
KCNV2-associated retinopathy: genotype-phenotype correlations - KCNV2 study group report 3.
Br J Ophthalmol. 2023 Oct 18:bjo-2023-323640. doi: 10.1136/bjo-2023-323640. Online ahead of print.
Br J Ophthalmol. 2023.
PMID: 37852740
Free article.
An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release.
Fleisher-Berkovich S, Battaglia V, Baratta F, Brusa P, Ventura Y, Sharon N, Dahan A, Collino M, Ben-Shabat S.
Fleisher-Berkovich S, et al.
Int J Mol Sci. 2023 Nov 13;24(22):16254. doi: 10.3390/ijms242216254.
Int J Mol Sci. 2023.
PMID: 38003444
Free PMC article.
Item in Clipboard
Selected cannabis cultivars modulate glial activation: in vitro and in vivo studies.
Fleisher-Berkovich S, Sharon N, Ventura Y, Feinshtein V, Gorelick J, Bernstein N, Ben-Shabat S.
Fleisher-Berkovich S, et al.
J Cannabis Res. 2024 May 22;6(1):25. doi: 10.1186/s42238-024-00232-0.
J Cannabis Res. 2024.
PMID: 38778343
Free PMC article.
Item in Clipboard
Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR, Boente CS, Crouch ER, Hubbard GB, Rogers DL, VanderVeen D, Yang MB, Cheung NL, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group.
Freedman SF, et al.
Ophthalmology. 2022 Oct;129(10):1120-1128. doi: 10.1016/j.ophtha.2022.05.019. Epub 2022 Jun 1.
Ophthalmology. 2022.
PMID: 35660415
Free PMC article.
Item in Clipboard
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
Gravina GL, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L, Landesman Y, McCauley D, Kauffman M, Shacham S, Festuccia C.
Gravina GL, et al.
BMC Cancer. 2015 Dec 1;15:941. doi: 10.1186/s12885-015-1936-z.
BMC Cancer. 2015.
PMID: 26620414
Free PMC article.
Item in Clipboard
Cite
Cite